We invest in Innovation
75%
of Chiesi’s turnover stems from internal research, but the pipeline also includes products that arise from collaborations and partnerships with other pharmaceutical companies.
1st
among Italian pharmaceutical companies investing in R&D in 2020, second among Italian manufacturing companies, and 13th among European pharmaceutical companies.
Source: European Commission,
Joint Research Centre, EU Industrial R&D Scoreboard2022
21,4%
of the Group’s turnover reinvested in R&D
42
patents filed in 2022. As such, Chiesi is among the pharmaceutical companies with the largest number of patents in Europe and is the first in Italy.
Source: European Patent Office, 2022 report
We intend to maintain our focus on our three primary therapeutic areas while also expanding our Research & Development programs to diversify and improve our range of treatments. This helps us achieve a balanced pipeline that features both promising studies with the potential for important breakthroughs and practical solutions for patients suffering from diseases with unmet therapeutic needs.
For more information about our therapeutical areas, go to our Pipeline page.
Our Global R&D Team
People in the Research & Development team represent our most fundamental asset. It is thanks to their knowledge and passion for science that Chiesi has been able to grow and establish itself in the pharmaceutical sector.
The R&D team is headquartered at the Research Center in Parma, Italy.
They collaborate closely with six other major research centers located in Paris (France), Chippenham (UK), Cary (USA), Lidingo (Sweden), Shanghai (China), and Toronto (Canada). Together, they focus on developing our global pipeline and increasing our productivity to support business growth goals.
Parma(italy), Paris (France), Chippenham (UK), Cary (USA), Lidingo (Sweden), Shanghai (China), and Toronto (Canada).
Chiesi’s R&D team consists of more than xx people worldwide, many of them - more than 65% - are women.
The R&D team leverages on diverse expertise and consists of four main units:
- R&D project and portfolio mangement;
- Research and pre-clinical development, including experimental pharmacology and translational science, drug design, pharmacokinetic;
- Clinical and technical development, including drug substance, pharmaceutical and device development; translational and precision medicine; real world evidence; data management and modeling;
- Quality assurance
The R&D team also supports products that have already made their way to the market through pharmacovigilance, intellectual property, regulatory activities, and active life cycle management programs of our products.